Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report

Available data on switching from originator infliximab to CT‐P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes. However, monitoring of such patients, especially in the early phase after switching, is important given the possibility that rare side e...

Descripción completa

Detalles Bibliográficos
Autores principales: Strik, Anne S., D’Haens, Geert R., Löwenberg, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878056/
https://www.ncbi.nlm.nih.gov/pubmed/31788249
http://dx.doi.org/10.1002/ccr3.2394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878056/
https://www.ncbi.nlm.nih.gov/pubmed/31788249
http://dx.doi.org/10.1002/ccr3.2394

Ejemplares similares